Michael Lilly to Disease-Free Survival
This is a "connection" page, showing publications Michael Lilly has written about Disease-Free Survival.
Connection Strength
0.256
-
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
Score: 0.105
-
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70.
Score: 0.083
-
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
Score: 0.042
-
Generation of "virtual" control groups for single arm prostate cancer adjuvant trials. PLoS One. 2014; 9(1):e85010.
Score: 0.027